New content published by 2 Minute Medicine.

• Stool biomarkers may be effective in the evaluation of necrotizing enterocolitis in preterm infants 26 October, 2026
  1. Stool biomarkers distinguished preterm infants with confirmed necrotizing enterocolitis (NEC) from preterm infants without NEC, with secretory immunoglobulin A showing the best individual discrimination. The post Stool biomarkers may be effective in the evaluation of necrotizing enterocolitis in preterm infants first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
  Siwen Liu
• Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results 26 October, 2026
  Amgen reported that tarlatamab plus durvalumab improved overall survival versus durvalumab alone in first-line maintenance treatment of extensive-stage small cell lung cancer. The post Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
  2 Minute Medicine
• Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results 26 October, 2026
  Company-reported final results showed sacituzumab tirumotecan improved overall survival versus platinum-based chemotherapy in EGFR-mutant advanced NSCLC. The post Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
  2 Minute Medicine
• Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial 26 October, 2026
  In a randomized phase 2 trial, camupepimut did not improve disease-free survival versus observation in patients with resected KRAS-mutated pancreatic cancer. The post Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
  2 Minute Medicine
• An electronic health record tool for exercise prescription may reduce fall rate among older adults 24 October, 2026
  1. In a large randomized clinical trial among 22 primary care practices, use of an electronic health record-integrated clinical decision support tool known as Electronic Strategies for Tailored Exercise to Prevent Falls (eSTEPS) significantly reduced the fall rate among older adults when in comparison to the control. The post An electronic health record tool for […]
  Lori Lai
• Optogenetic therapy may partially restore vision in retinitis pigmentosa 23 October, 2026
  1. In this phase 1 trial involving subjects with advanced retinitis pigmentosa, optogenetic therapy was associated with improved light sensitivity and partial recovery of visual function. 2. Most ocular adverse events were mild or moderate, although a severe, transient central retinal artery occlusion occurred immediately after injection and resolved within minutes. The post Optogenetic therapy […]
  Zhenyu Li